SynthesisFrontiers in pharmacology2025
Pediatric efficacy and safety in common cold treated with herbal medicine (PEACH): a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The common cold is one of the most frequent illnesses in children, yet effective and safe treatments remain limited. Concerns regarding the safety of conventional medications persist. Herbal medicine (HM) has long been used, but the quantity and certainty of evidence in children have not been systematically summarized. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) following PRISMA guidelines (PROSPERO CRD42024610421). Nine databases were searched to October 2024. Eligible studies included pediatric patients (<19 years) treated with oral HM compared with conventional medicine, placebo, or no treatment. Risk of bias was assessed with RoB 2, and certainty of evidence was rated using GRADE. Results: Sixty-six RCTs involving 7,176 participants were included. HM significantly improved total effective rate compared with conventional medicine (RR = 1.16, 95% CI [1.12-1.21]), with combination therapy providing additional benefits (RR = 1.17, 95% CI [1.13-1.22]). HM shortened overall symptom improvement time (SMD = -1.01, 95% CI [-1.41, -0.60]) and reduced total symptom severity (SMD = -0.80, 95% CI [-1.22, -0.38]) compared with conventional medicine. Both HM monotherapy and combination therapy demonstrated a markedly lower incidence of adverse events compared with conventional medicine (RR = 0.28, 95% CI [0.20, 0.40] and RR = 0.53, 95% CI [0.32, 0.88], respectively), with reported events being mild and mainly gastrointestinal. The certainty of evidence was predominantly moderate according to the GRADE assessment, increasing confidence in these findings. Conclusion: HM appears effective and safe for pediatric common cold, providing faster recovery and fewer adverse events. These findings, supported by moderate-certainty evidence, justify consideration of HM in pediatric care, although further high-quality, multicenter RCTs are needed. Systematic Review Registeration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=610421, identifier CRD42024610421.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.